Back

INVICTUS - Rivaroxaban versus VKA for rheumatic atrial fibrillation.

3 December 2022 (11:02 - 11:12)
Organised by:
Congress Presentation Part of: Hot Line: Miscellaneous Other ESC Professional Premium Access ESC Asia 2022 with APSC & AFC

About the speaker

Photo
Associate Professor Quang Ngoc Nguyen

Vinmec Healthcare System, Hanoi (Viet Nam)

8 More presentations in this session

Presentation thumbnail
ESC TV Interview - INVICTUS - Rivaroxaban versus VKA for rheumatic atrial fibrillation.
Video
Presentation thumbnail
ESC TV Interview - EchoNet-RCT - Safety and Efficacy Study of AI LVEF.
Video
Presentation thumbnail
EchoNet-RCT - Safety and Efficacy Study of AI LVEF.
Doctor V. Delgado (Barcelona, ES)
Video
Presentation thumbnail
ESC TV Interview - eBRAVE-AF - Smartphone-based AF screening.
Video
Presentation thumbnail
eBRAVE-AF - Smartphone-based AF screening.
Doctor A. Fong (Kuching, MY)
Video

Access the full session

Session thumbnail
Hot Line: Miscellaneous
Video

The Event

Event poster

ESC Asia 2022 with APSC & AFC

3 December 2022 11:02 CET
You may be interested in
thumbnail
Congress Presentation
Discussant review - INVICTUS.
28 August 2022
thumbnail
Congress Presentation
Rivaroxaban dosing in patients with atrial fibrillation: results from the RIVER registry- is dosing according to renal function appropriate?
27 August 2021
thumbnail
Congress Presentation
Direct oral anticoagulants vs warfarin in non-valvular atrial fibrillation. Meta-analysis, includes all published trials.
27 August 2021
thumbnail
Congress Presentation
Ophthalmic complications in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin
25 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources